UroGen's UGN-103 demonstrates 94.5% six-month response in bladder cancer trial, offering simplified manufacturing over existing ZUSDURI therapy.

Roche's giredestrant demonstrates 30% reduction in breast cancer recurrence or death in the lidERA trial, with FDA filing implications...

Regeneron's fianlimab misses primary endpoint in Phase 3 melanoma trial, posting p-value of 0.0627 despite 5.1-month PFS improvement over...

Senti Bio advances SENTI-202 pivotal trial with Donor X selection strategy, achieving 50% complete remission in heavily pretreated R/R...

Alumis reports 68% PASI 90 response for envudeucitinib in psoriasis trial ONWARD1, matching deucravacitinib efficacy with early scalp clearance...

Cardiff Oncology advances onvansertib Phase 3 for RAS-mutated metastatic colorectal cancer with 72.2% response rate in Phase 2 data.

NBTXR3 achieves 57% complete response rate in stage III lung cancer study, compared to under 5% with current standard...

UroGen's UGN-103 demonstrated 94.5% six-month response rate in Phase 3 NMIBC trial, edging prior standard ZUSDURI's efficacy benchmark.

Regeneron's fianlimab melanoma trial missed statistical significance for progression-free survival, though the high-dose combination showed a 5.1-month numeric

Signant Health's acquisition of Ametris on May 14 consolidates eCOA and wearable data streams—and exposes the real cost of...